References

1. [1]. Pieske BM ALDO-DHF: Aldosterone Receptor Blockade in Diastolic Heart Failure. European Society of Cardiology 2012 Congress, Munich, Germany at < http://www.eurekalert.org/pubreleases/2012-08/esoc-tas082,612.php>
2. [2]. ElGuindy, A. & Yacoub, M. Review article: Heart Failure with Preserved Ejection Fraction. Global Cardiology Science and Practice 2012–10
3. [3]. B. a Borlaug., , W.J Paulus. . Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. . European heart journal . 2011; ; 32: : 670– – 9
   [Google Scholar]
4. [4]. A.S. Desai , et al. . Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. . American heart journal . 2011; ; 162: : 966– – 97.e10
   [Google Scholar]
5. [5]. The PARAMOUNT study. at < http://www.eurekalert.org/pubreleases/2012-08/esoc-tps10,82612.php>
6. [6]. S.D. Solomon , et al. . The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. . The Lancet . 2012;: doi:10.1016/S0140–6736(12)61,227-6
   [Google Scholar]
7. [7]. M.P. Lefkowitz. . LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure and hypertension. . BMC Pharmacology . 2011; ; 11: : O3
   [Google Scholar]
8. [8]. A. Martinez-Rumayor., , A.M. Richards., , J.C. Burnett., , J.L. Januzzi. . Biology of the natriuretic peptides. . The American journal of cardiology . 2008; ; 101: : 3– – 8
   [Google Scholar]